Population-level Outcomes of Ex-Vivo Lung Perfusion (EVLP) in Lung Transplantation

Abstract

Introduction

Ex-vivo lung perfusion (EVLP) is a novel organ preservation technique introduced to assess extended lung donors and determine their suitability for human use.

Material and Methods

This retrospective cohort study analyzed lung transplant recipients in the U.S. from 2011 to 2021, using data from the Scientific Registry of Transplant Recipients (SRTR). Kaplan-Meier curves were used for time-to-event survival analysis, and the Cox proportional hazards model was used to determine hazard ratios for overall survival.

Results

Of 23,261 patients, 608 had EVLP-donor lungs. The 5-year survival was similar across groups. Centers with EVLP access had median wait times of 48 days (SD 260.80) versus 68 days (SD 273.73) at other centers. Cox proportional hazards model showed no significant disparity in 5-year survival with EVLP (HR 1.14, p 0.08), gender (HR 1.04, p 0.07), and high volume (HR 0.8, p 0.07). Perioperative extracorporeal membrane oxygenation (ECMO) (HR 1.29, p < 0.01) and black recipient race (HR 1.15, p < 0.01) influenced survival; there were no statistical differences in any other race. Black EVLP-assessed recipients showed a nonsignificant trend toward a survival benefit (p = 0.26) with a 14.2% higher 5-year survival (95% CI 2.7–28.7).

Conclusion

EVLP has not adversely affected 5-year survival rates in lung transplantation recipients and is associated with shorter wait times. A survival advantage in black recipients with EVLP-assessed lungs needs further research.

Keywords

transplantation - lung - organ preservation - transplantation - heart–lung - surgery/incisions - surgery - complications

Publikationsverlauf

Eingereicht: 10. Dezember 2024

Angenommen: 11. April 2025

Accepted Manuscript online:
15. April 2025

Artikel online veröffentlicht:
20. Mai 2025

• References

• 1 Tian D, Wang Y, Shiiya H. et al. Outcomes of marginal donors for lung transplantation after ex vivo lung perfusion: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2020; 159 (02) 720-730.e6
• 2 Cypel M, Keshavjee S. Extracorporeal lung perfusion (ex-vivo lung perfusion). Curr Opin Organ Transplant 2016; 21 (03) 329-335
• 3 Divithotawela C, Cypel M, Martinu T. et al. Long-term outcomes of lung transplant with ex vivo lung perfusion. JAMA Surg 2019; 154 (12) 1143-1150
• 4 Yeung JC, Krueger T, Yasufuku K. et al. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. Lancet Respir Med 2017; 5 (02) 119-124
• 5 Cypel M, Keshavjee S. Strategies for safe donor expansion: donor management, donations after cardiac death, ex-vivo lung perfusion. Curr Opin Organ Transplant 2013; 18 (05) 513-517
• 6 Ribeiro RVP, Ku T, Wang A. et al. Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin. J Heart Lung Transplant 2022; 41 (03) 287-297
• 7 Galasso M, Feld JJ, Watanabe Y. et al. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nat Commun 2019; 10 (01) 481
• 8 Wang A, Ribeiro RVP, Ali A. et al. Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs. Sci Transl Med 2022; 14 (632) eabm7190
• 9 Jawitz OK, Raman V, Becerra D. et al. Lung transplantation after ex vivo lung perfusion: early outcomes from a US national registry. Ann Surg 2022; 275 (05) 1006-1012